Optimization of cisplatin doses in a testicular cancer patient with acute renal failure

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Anne-Lise PouliquenF Lokiec

Abstract

Although testicular cancers are highly curable malignancies, conventional cisplatin based therapy often causes important toxicities, not often easily manageable. Nephrotoxicity occurs in almost all patients, and is potentialized in patients suffering from renal failure. Monitoring of residual levels of unbound platinum was used to define guidelines for cisplatin administration. Monitoring of cisplatin was initiated in a patient treated for metastatic testicular cancer and acute renal failure. Reduced doses of cisplatin were first administered in conjunction with hemodialysis. Unbound and total platinum levels were determined by flameless atomic absorption spectrophotometry. The data found allowed us to adapt and increase sequentially cisplatin doses, accordingly with the renal function. Full regimen doses were eventually administered when useful renal function returned. This simple approach may be useful in monitoring cisplatin administration during acute renal failure.

References

Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C R NicholsL H Einhorn
Sep 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A ReeceP G Gill
Sep 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V RibragG G Chabot
Jul 24, 1997·The New England Journal of Medicine·G J Bosl, R J Motzer
Dec 7, 2000·Clinical Pharmacokinetics·H J van den BongardJ H Schellens
May 6, 2004·Cancer Chemotherapy and Pharmacology·Felix E de JonghAlex Sparreboom
May 21, 2004·British Journal of Clinical Pharmacology·Sail Urien, François Lokiec
Jun 2, 2004·Clinical Pharmacokinetics·Masatoshi TomitaKenichi Tanaka
Dec 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer

❮ Previous
Next ❯

Citations

Oct 6, 2020·Expert Opinion on Drug Metabolism & Toxicology·Maud MaillardEtienne Chatelut

❮ Previous
Next ❯

Related Concepts

Related Feeds

© 2022 Meta ULC. All rights reserved